Print ISSN:-2394-2789
Online ISSN:-2394-2797
CODEN : IJPCN9
Original Article
Author Details :
Volume : 4, Issue : 3, Year : 2017
Article Page : 54-58
Abstract
Teneligliptin was estimated in tablet form by ultraviolet-spectrophotometric methods followed by distilled water as solvent. Here three methods were used for quantitative estimation of teneligliptin in tablet dosage form. Quantitative estimation of pure drug solution was done at ?max of 244 nm for method I. For measurement of response in method II peak minima of 266.4 nm was selected. Wavelength range of 238.6-247.8 nm was selected for calculating area in area under the curve method. Validation of the methods was performed according to guidelines of International Conference on Harmonisation. The % assay of the formulation by the three methods was in the range of 100.17-100.74. Graph was linear in the range of 5-70 µg/mL for zero order and AUC techniques, while 5-80 µg/mL for first order derivative technique. Good correlation between response and concentration was found as the value of regression coefficient (R2) was 0.999. The accuracy of the drug was ranged in between 98.54-101.80 for all ultraviolet-spectrophotometric methods and was in acceptable range. The percentage RSD values for method precision for all the methods were within the limit of ? 2. From the data it was concluded that the methods developed have scope to be applied for quantitative estimation of pure drug of teneligliptin in pharmaceutical dosage form.
Keywords: Ultra Violet-Spectrophotometry, Teneligliptin, Peak minima, AUC technique
How to cite : Yadav N, Goyal A, Method development and validation of Teneligliptin in pharmaceutical dosage form by UV spectrophotometric methods. Int J Pharm Chem Anal 2017;4(3):54-58
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.